Heshani Desilva

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial

Nizar M. Tannir, Laurence Albigès, David F. McDermott et al. · Annals of Oncology · 2024 · 192 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Sensitivity of Small Cell Lung Cancer to BET Inhibition Is Mediated by Regulation of <i>ASCL1</i> Gene Expression

Ryan Lenhart, Stefan Kirov, Heshani Desilva et al. · Molecular Cancer Therapeutics · 2015 · 96 citations

Medicine, Molecular Biology, Oncology +17

Inhibition of Casein Kinase 2 Disrupts Differentiation of Myeloid Cells in Cancer and Enhances the Efficacy of Immunotherapy in Mice

Ayumi Hashimoto, Chan Gao, Jérôme Mastio et al. · Cancer Research · 2018 · 48 citations · Full text

Medicine, Immunology, Oncology +17

Nivolumab plus ipilimumab (NIVO+IPI) vs sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC): Long-term follow-up data from the phase 3 CheckMate 214 trial.

Nizar M. Tannir, Bernard Escudier, David F. McDermott et al. · Journal of Clinical Oncology · 2024 · 46 citations

Medicine, Oncology, Pharmacotherapy +16

FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy

Toni K. Choueiri, Harriet M. Kluger, Saby George et al. · Journal for ImmunoTherapy of Cancer · 2022 · 38 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17